PMID- 26851047
OWN - NLM
STAT- MEDLINE
DCOM- 20160712
LR  - 20160206
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 36
IP  - 2
DP  - 2016 Feb
TI  - Stereotactic Body Radiation Therapy (SBRT) for Recurrent Non-small Cell Lung 
      Cancer (NSCLC).
PG  - 825-8
AB  - AIM: For local recurrence of non-small cell lung cancer (NSCLC), stereotactic 
      body radiation therapy (SBRT) has become increasingly popular. Many patients with 
      recurrent NSCLC are unable to receive high-dose SBRT [biologically effective dose 
      (BED) >100 Gy] due to poor performance status and potential normal tissue damage. 
      PATIENTS AND METHODS: Thirty-one patients receiving lower-dose SBRT with a BED of 
      57.6 to 96.0 Gy, were analyzed for local control, freedom from distant 
      progression and survival. RESULTS: In the entire series, local control rates were 
      96% at 1, 2 and 3 years. Freedom from distant progression rates were 74%, 65% and 
      65%, respectively, and survival rates were 87%, 65% and 65%, respectively. On 
      multivariate analysis, freedom from distant progression was significantly 
      associated with absence of distant metastases (p=0.009), and survival with BED 
      >75 Gy (p=0.039). CONCLUSION: SBRT with BED <100 Gy provided very promising 
      outcomes when administered for recurrent NSCLC. A BED >75 Gy is recommended, 
      which was superior to lower doses.
CI  - Copyright(c) 2016 International Institute of Anticancer Research (Dr. John G. 
      Delinassios), All rights reserved.
FAU - Janssen, Stefan
AU  - Janssen S
AD  - Department of Radiation Oncology, University of Lubeck, Lubeck, Germany Medical 
      Practice for Radiotherapy and Radiation Oncology, Hannover, Germany.
FAU - Kasmann, Lukas
AU  - Kasmann L
AD  - Department of Radiation Oncology, University of Lubeck, Lubeck, Germany.
FAU - Rudat, Volker
AU  - Rudat V
AD  - Department of Radiation Oncology, Saad Specialist Hospital, Al Khobar, Kingdom of 
      Saudi Arabia.
FAU - Rades, Dirk
AU  - Rades D
AD  - Department of Radiation Oncology, University of Lubeck, Lubeck, Germany 
      rades.dirk@gmx.net.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
SB  - IM
MH  - Aged
MH  - Carcinoma, Non-Small-Cell Lung/mortality/secondary/*surgery
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/mortality/pathology/*surgery
MH  - Male
MH  - Multivariate Analysis
MH  - *Neoplasm Recurrence, Local
MH  - Proportional Hazards Models
MH  - *Radiosurgery/adverse effects/mortality
MH  - Radiotherapy Dosage
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Survival Rate
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Non-small cell lung cancer
OT  - biologically effective dose
OT  - local recurrence
OT  - stereotactic body radiation therapy
EDAT- 2016/02/07 06:00
MHDA- 2016/07/13 06:00
CRDT- 2016/02/07 06:00
PHST- 2016/02/07 06:00 [entrez]
PHST- 2016/02/07 06:00 [pubmed]
PHST- 2016/07/13 06:00 [medline]
AID - 36/2/825 [pii]
PST - ppublish
SO  - Anticancer Res. 2016 Feb;36(2):825-8.